<DOC>
	<DOC>NCT01630369</DOC>
	<brief_summary>Primary Objective: - To evaluate the decrease of Hb A1c â‰¥ 1% after 6 month treatment in patients with Type 2 Diabetes Mellitus (T2DM) uncontrolled on Oral Antidiabetics (OADs) Secondary Objectives: - To evaluate the percentage of patients with Hb A1c &lt; 7.5%, - To evaluate the rate of hypoglycaemia (symptomatic, severe) - To evaluate the middle dose of insulin per product - Insuman Basal, Insuman Comb, Insuman Rapid after 6 month treatment - To evaluate the change in Fasting Plasma Glucose (FPG) after 6 month treatment - To assess the overall safety - To evaluate the efficacy of education courses in Diabetes Schools (% of correct answers after second test compare to the testing of the initial level)</brief_summary>
	<brief_title>Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>6 months</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criteria : T2DM patients uncontrolled by maximum tolerated dose of 12 OADs Males and Female &gt; 18 years HbA1c &gt; 7.5% Patients with abilities of selfmonitoring of Diabetes, managing of patient's diary, ability to obtain education in Diabetes School, completion of Questionnaire It is expected that the patient will remain on a stable dose of OADs within 6 months of treatment Exclusion criteria : Type 1 diabetes Current temporary insulin therapy (gestational diabetes, pancreas cancer, surgery, clinical trial) Any clinically significant acute major organ or systemic diseases making interpretation of the evaluation results difficult Patient planning a pregnancy now or in the next 6 months The patient is participating in another clinical study now or in the last 28 days prior to Visit 1 The patient is a drug user (currently or in the past) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>